iqvia semaglutide tirzepatide prescriptions q3 2024 us Off-patent semaglutide in 2026: the next revolution in anti-obesity medications ZhiKe | Tirzepatide Rakes in

Which compound has more published research data available?# Tirzepatide has substantially more published research data as of 2026 because it entered clinical development earlier and has a larger completed trial program across the SURPASS and SURMOUNT study families covering type 2 diabetes, obesity, sleep-disordered breathing, and cardiometabolic endpoints

The Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study

The companys approach to covering weight loss medications depends on several factors and can vary significantly

4 Your GP should monitor your blood pressure as you lose weight, in case your ramipril dose needs reducing

(3) Concomitant use of GLP-1R agonist or dipeptidyl peptidase-4 inhibitors